Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cetirizine injection - TerSera Therapeutics

Next Previous
Search
Drug Profile

Cetirizine injection - TerSera Therapeutics

Alternative Names: JDP-205; JDP-205 Al; JDP-207; QUZYTTIR; QZYTIR

Latest Information Update: 29 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator JDP Therapeutics
  • Developer TerSera Therapeutics
  • Class Acetic acids; Antiallergics; Benzyl compounds; Chlorobenzenes; Eye disorder therapies; Nonsedating antihistamines; Piperazines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Urticaria
  • Phase II Hypersensitivity

Most Recent Events

  • 03 Jun 2021 Updated efficacy and adverse events data from a phase II trial in Hypersensitivity presented at the 57th Annual Meeting of the American Society of Clinical Oncology (ASCO-2021)
  • 05 Mar 2021 Efficacy and adverse events data from a phase II trial in Hypersensitivity released by TerSera Therapeutics
  • 23 Feb 2021 Centers for Disease Control and Prevention (CDC) adds cetirizine injection as an adjunctive therapy to its guidelines for managing adverse reactions after COVID-19 vaccination

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top